

Ref. No.: NLL/CS/2025 - 606

November 11, 2025

To,
National Stock Exchange of India Limited
Listing Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai 400 051

Symbol: NECLIFE

BSE Limited
Corporate Relationship Department,
P J Towers, Dalal Street,
Mumbai 400 001
Script Code: 532649

Sub: Disclosure under Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations") – Transfer of key managerial personnel pursuant to slump sale

Ref: Stock exchange intimation vide letter no. NLL/CS/2025- 605 dated November 11, 2025.

Dear Sir/ Madam,

Pursuant to Regulation 30 of the SEBI LODR Regulations and further to the aforesaid stock exchange intimations relating to the: (i) business transfer agreement ("**BTA**") executed between Nectar Lifesciences Limited ("**Company**") and Ceph Lifesciences Private Limited ("**Purchaser**") dated July 07, 2025 we wish to inform you that following the completion of the transactions contemplated under the BTA, the following key managerial personnel ("**KMP**") and senior management personnel ("**SMP**") of the Company have been transferred to the Purchaser, effective from November 10, 2025:

1. Dr. Surulichamy Senthilkumar, Wholetime Director designated as Director (R&D);
2. Mr. Amit Chadah, Chief Executive Officer;
3. Mr. Harparkash Singh Gill, President; and
4. Mr. Parveen Kumar Sareen, Vice- President (Technical)

Please note that Dr. Surulichamy Senthilkumar shall be continuing as a Non-Executive Director of the Company (without any remuneration and sitting fee). A letter from him to this effect is attached herewith for your ready reference.

The requisite details regarding cessation/ transfer of KMP and SMP required under the SEBI LODR Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, and as amended upto date, are provided in **Annexure A**.

Kindly take the same on record.

Yours faithfully,
For **Nectar Lifesciences Limited**

(Sanjaymohan Singh Rawat)
Company Secretary & Compliance Officer

Annexure- A

Details as required as per LODR Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, and as amended upto date, are as follows:

Sr. No.	Particulars	Disclosures			
		Dr. Surulichamy Senthilkumar*	Mr. Amit Chadah	Mr. Harparkash Singh Gill	Mr. Parveen Kumar Sareen
1.	Reason for change viz. Appointment, re-appointment, resignation, removal, death or otherwise	Cessation of employment with the Company and transfer to Ceph Lifesciences Private Limited ("Purchaser") in accordance with the terms of the business transfer agreement dated July 07, 2025, executed between the Company and Purchaser.			
2.	Date of appointment/re-appointment/ cessation (as applicable) & term of appointment/ re-appointment	November 10, 2025			
3.	Brief profile (in case of appointment)	Not Applicable ("NA")	NA	NA	NA
4.	Disclosure of relationships between directors (in case of appointment of a director)	NA	NA	NA	NA

* Dr. Surulichamy Senthilkumar shall be continuing as a Non-Executive Director of the Company (without any remuneration and sitting fee).

10 November, 2025

To,
The Board of Directors
Nectar Lifesciences Limited ("**Company**")
Village Saidpura, Tehsil Derabassi,
Distt. S.A.S. Nagar (Mohali), Punjab

Sub.: Resignation as a Director as well as Whole-time Director of the Company

Dear Sirs/ Madams,

This is with reference to the Business Transfer Agreement dated July 07, 2025 ("**BTA**") between the Company and Ceph Lifesciences Private Limited (hereinafter referred to as the "**Purchaser**") for transfer of the Company's business related to the manufacture, distribution, marketing and sale of active pharmaceutical ingredients and formulations (the "**Slump Sale**") to the Purchaser. As per the terms of the BTA, the employees of the Company, including myself, are to be transferred to the Purchaser, today.

As I am also being transferred as part of this process, I wish to formally resign from my position as a Wholetime Director designated as Director (R&D) of the Company, effective immediately, in accordance with the Slump Sale.

I will be continuing as a Non-Executive Director of the Company (without any remuneration and sitting fee), till further notice.

I want to express my sincere gratitude for the opportunity to serve as part of the leadership team.

I extend my best wishes for continued success to you and the Company in the future.

Sincerely,



(**Surulichamy Senthilkumar**)

Whole-time Director
Nectar Lifesciences Limited
DIN: 11124083